FDA Brief

Warning letters Food

FDA warning letter to

Mother Earth Minerals, Inc.

High riskIssued Mar 28, 2025Posted Jun 3, 2025Human Foods Program

FDA warns Mother Earth Minerals that its Calcium, Magnesium and Silver are unapproved drugs with disease claims and lack quality controls.

What happened

FDA inspected the company's Ogden, Utah facility between August 7 and 15, 2024 and reviewed the product labels collected there, then reviewed the website meminerals.com in September 2024 and January 2025. The website and labels recommend Calcium, Magnesium and Silver for cancer, multiple sclerosis, diabetes and other diseases, which makes them unapproved new drugs. The inspection also found the firm had no ingredient or finished-product specifications, no master manufacturing records, no written quality control procedures and no reserve samples.

What FDA found

  1. The company set no specifications for its ingredients or finished products — not for identity, purity, strength, contamination limits, or labels and packaging.

    21 CFR 111.70
  2. The company had no written master manufacturing record for any product or batch size.

    21 CFR 111.205(a)
  3. Batch production records were missing required details such as lot numbers, component weights, yields, the initials of people who weighed or added ingredients, labels, and quality control release.

    21 CFR 111.255(b); 21 CFR 111.260
  4. The company had no written quality control procedures and could not show that any quality control work was done.

    21 CFR 111.103
  5. The company did not keep reserve samples of any finished lot it distributed.

    21 CFR 111.83
  6. The products were promoted on the website and labels to treat or prevent cancer, multiple sclerosis, diabetes, AIDS and other diseases, so they are unapproved new drugs and carry no adequate directions for use.

    21 U.S.C. 321(p), 355(a), 352(f)(1)

What FDA wants

FDA asks the company to reply in writing within 15 working days with the specific steps taken to fix each violation, copies of supporting records, and how it will prevent recurrence. If the fixes are not complete by then, the company must explain the delay and give a date for finishing.

Who should pay attention

  • retailers and online marketplaces that sell liquid mineral supplements
  • contract manufacturers and packagers asked to run products with no specifications or batch records
  • consumers and buyers of mineral supplements marketed for serious diseases

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk